Exploring Managing Immunotherapy Toxicities In Melanoma
Exploring Managing Immunotherapy Toxicities In Melanoma reveals several interesting facts.
- Omid Hamid, MD, leads the panel discussion on the safety of nivolumab and
- In our third episode of our special vodcast series, Redefining
- Michael B. Atkins, MD, describes recognizing and
- Michael A. Postow, MD, and Claire Crowley, RN, discuss the overall
- Dr Au speaks with ecancer at the ACP
In-Depth Information on Managing Immunotherapy Toxicities In Melanoma
Michael A. Postow, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, shares advice to community oncologists ... Dr. Medina is an Assistant Professor of medicine in the Division of Medical Oncology at the University of Colorado Anschutz ... Tune in as Panelists Robert H.I. Andtbacka, MD, CM; Antoni Ribas, MD, PhD; Michael A. Davies, MD, PhD; Michael A. Postow, MD; and ...
Michael B. Atkins, MD, describes recognizing and
Stay tuned for more updates related to Managing Immunotherapy Toxicities In Melanoma.
